{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Neutropenia CTCAE Grade ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Febrile neutropenia CTCAE Grade ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Thrombocytopenia CTCAE Grade ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Leukopenia CTCAE Grade ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypertension CTCAE Grade ≥3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Toxicity will be assessed and graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0, after each cycle.","groups":[{"description":"Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nDecitabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRecombinant EphB4-HSA Fusion Protein: Given IV","id":"OG000","title":"Treatment (sEphB4-HSA, Azacitidine, Decitabine)"}],"paramType":"NUMBER","populationDescription":"Safety analysis includes all participants who completed 2 cycles of treatment.","reportingStatus":"POSTED","timeFrame":"Up to 13 months (up to 12 cycles + 30 days) from the start of treatment.","title":"Assessment of Toxicity to Hypomethylating Agent (HMA)","type":"PRIMARY","unitOfMeasure":"Participants"}